Track market-moving stories before they get noisy

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System trimmed its holdings in shares of The Ensign Group, Inc. (NASDAQ:ENSG – Free Report) by 7.5% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 134,667 shares of the company’s stock after selling 10,863 shares during the quarter. California Public Employees Retirement System owned 0.23% of The Ensign Group worth $27,135,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Mitsubishi UFJ Trust & Banking Corp increased its position in shares of The Ensign Group by 52.5% during the 4th quarter. Mitsubishi UFJ Trust & Banking Corp now owns 54,336 shares of the company’s stock valued at $9,465,000 after purchasing an additional 18,699 shares during the last quarter. Cypress Wealth Services LLC purchased a new position in shares of The Ensign Group in the 4th quarter worth about $1,508,000. SG Americas Securities LLC boosted its holdings in shares of The Ensign Group by 70.2% in the 4th quarter. SG Americas Securities LLC now owns 38,029 shares of the company’s stock worth $6,625,000 after buying an additional 15,683 shares during the last quarter. Fort Washington Investment Advisors Inc. OH grew its position in The Ensign Group by 8.4% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 163,131 shares of the company’s stock valued at $28,417,000 after buying an additional 12,602 shares during the period. Finally, Allspring Global Investments Holdings LLC grew its position in The Ensign Group by 14.9% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 129,756 shares of the company’s stock valued at $22,567,000 after buying an additional 16,853 shares during the period. 96.12% of the stock is currently owned by institutional investors.

Insider Activity In other news, Director Barry M. Smith sold 700 shares of the business’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $164.28, for a total value of $114,996.00. Following the sale, the director owned 21,352 shares of the company’s stock, valued at $3,507,706.56. The trade was a 3.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.00% of the stock is currently owned by company insiders.

Analysts Set New Price Targets A number of research firms recently issued reports on ENSG. Truist Financial decreased their price objective on shares of The Ensign Group from $215.00 to $202.00 and set a “hold” rating for the company in a report on Tuesday, July 14th. Wall Street Zen raised shares of The Ensign Group from a “hold” rating to a “buy” rating in a research report on Sunday, June 14th. Weiss Ratings downgraded shares of The Ensign Group from a “buy (b)” rating to a “buy (b-)” rating in a research report on Tuesday, June 16th. Zacks Research lowered shares of The Ensign Group from a “strong-buy” rating to a “hold” rating in a research note on Monday, April 6th. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of The Ensign Group in a report on Tuesday, June 9th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $213.50.

Get Our Latest Report on ENSG

The Ensign Group Stock Down 0.7% ENSG stock opened at $170.87 on Wednesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.56 and a current ratio of 1.56. The company has a market capitalization of $9.99 billion, a price-to-earnings ratio of 27.83, a PEG ratio of 1.68 and a beta of 0.69. The Ensign Group, Inc. has a fifty-two week low of $134.79 and a fifty-two week high of $218.00. The stock has a fifty day moving average of $165.80 and a 200-day moving average of $184.01.

The Ensign Group (NASDAQ:ENSG – Get Free Report) last announced its quarterly earnings data on Thursday, April 30th. The company reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.79 by $0.06. The Ensign Group had a return on equity of 16.78% and a net margin of 6.89%.The business had revenue of $1.39 billion for the quarter, compared to analysts’ expectations of $1.40 billion. During the same period in the previous year, the business posted $1.52 EPS. The firm’s quarterly revenue was up 18.4% compared to the same quarter last year. The Ensign Group has set its FY 2026 guidance at 7.480-7.620 EPS. As a group, equities research analysts predict that The Ensign Group, Inc. will post 6.82 earnings per share for the current year.

The Ensign Group Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be paid a $0.065 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $0.26 annualized dividend and a dividend yield of 0.2%. The Ensign Group’s dividend payout ratio (DPR) is presently 4.23%.

About The Ensign Group (Free Report)

The Ensign Group, Inc is a diversified provider of post-acute healthcare services in the United States, operating a network of skilled nursing, assisted living, independent living, home health and hospice care centers. The company’s model emphasizes integrated care by employing multidisciplinary teams—including nursing staff, therapists and physicians—to deliver personalized rehabilitation and long-term care services for seniors and other patients recovering from injury, illness or surgery.

Through its owned and managed centers, The Ensign Group offers a broad spectrum of rehabilitation services such as physical, occupational and speech therapy.

Featured Articles Five stocks we like better than The Ensign Group Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding ENSG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Ensign Group, Inc. (NASDAQ:ENSG – Free Report).

Receive News & Ratings for The Ensign Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Ensign Group and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDimensional Fund Advisors LP Acquires 213,051 Shares of Aon plc $AON

NEXT HEADLINE »Dimensional Fund Advisors LP Acquires 834,885 Shares of Carnival Corporation $CCL

GREEN BAY, Wis.--(BUSINESS WIRE)--Transporting refrigerated goods requires coordination, specialized expertise and best-in-class equipment. As a reliable carrier, Schneider is focused on the precise timing, execution and on-time service that are critical given the regulatory requirements surrounding consumer-grade fresh food. Reinforcing its expertise in dedicated refrigerated shipping, Schneider National, Inc. (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logist.

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.

Posted by Defense World Staff on Jul 22nd, 2026

Bank of New York Mellon Corp lessened its stake in Tyler Technologies, Inc. (NYSE:TYL – Free Report) by 48.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 268,754 shares of the technology company’s stock after selling 255,274 shares during the quarter. Bank of New York Mellon Corp owned approximately 0.64% of Tyler Technologies worth $92,016,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Principal Financial Group Inc. increased its position in Tyler Technologies by 3.1% during the fourth quarter. Principal Financial Group Inc. now owns 1,454,061 shares of the technology company’s stock worth $660,089,000 after buying an additional 43,421 shares during the last quarter. TimesSquare Capital Management LLC raised its stake in Tyler Technologies by 7.6% in the fourth quarter. TimesSquare Capital Management LLC now owns 111,702 shares of the technology company’s stock valued at $50,707,000 after buying an additional 7,913 shares during the period. Norges Bank acquired a new stake in shares of Tyler Technologies in the fourth quarter valued at approximately $921,035,000. Comerica Bank lifted its position in shares of Tyler Technologies by 67.2% in the fourth quarter. Comerica Bank now owns 29,571 shares of the technology company’s stock valued at $13,424,000 after buying an additional 11,889 shares during the last quarter. Finally, UBS Group AG boosted its stake in shares of Tyler Technologies by 6.0% during the 4th quarter. UBS Group AG now owns 224,644 shares of the technology company’s stock worth $101,977,000 after acquiring an additional 12,673 shares during the period. 93.30% of the stock is owned by institutional investors.

Tyler Technologies Trading Down 5.7% NYSE:TYL opened at $299.88 on Wednesday. The stock has a 50 day simple moving average of $304.71 and a 200 day simple moving average of $341.36. The stock has a market cap of $12.65 billion, a P/E ratio of 41.42, a PEG ratio of 2.11 and a beta of 0.82. Tyler Technologies, Inc. has a 1-year low of $270.71 and a 1-year high of $621.34.

Tyler Technologies (NYSE:TYL – Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The technology company reported $3.09 EPS for the quarter, beating analysts’ consensus estimates of $3.01 by $0.08. The firm had revenue of $613.50 million for the quarter, compared to analyst estimates of $608.66 million. Tyler Technologies had a return on equity of 10.74% and a net margin of 13.26%.The company’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same period in the prior year, the firm posted $2.78 EPS. Tyler Technologies has set its FY 2026 guidance at 12.500-12.750 EPS. As a group, sell-side analysts forecast that Tyler Technologies, Inc. will post 10.04 EPS for the current year.

Analyst Upgrades and Downgrades A number of research analysts recently weighed in on the company. Robert W. Baird set a $455.00 target price on Tyler Technologies in a report on Friday, May 1st. Cantor Fitzgerald lifted their price objective on shares of Tyler Technologies from $325.00 to $360.00 and gave the stock a “neutral” rating in a research report on Friday, May 1st. Weiss Ratings downgraded shares of Tyler Technologies from a “hold (c-)” rating to a “sell (d+)” rating in a report on Friday, April 24th. Citizens Jmp reissued a “market outperform” rating and issued a $500.00 price objective on shares of Tyler Technologies in a research report on Tuesday, April 28th. Finally, Truist Financial set a $440.00 target price on shares of Tyler Technologies in a research note on Friday, May 1st. Thirteen investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Tyler Technologies has an average rating of “Moderate Buy” and an average target price of $472.38.

Read Our Latest Stock Analysis on Tyler Technologies

About Tyler Technologies (Free Report)

Tyler Technologies, Inc is a provider of software and technology services for the public sector, delivering integrated systems that help government and public agencies manage operations, finances and citizen services. Headquartered in Plano, Texas, the company focuses on developing and implementing solutions for local and state governments, school districts, courts and public safety organizations. Its offerings are aimed at modernizing administrative workflows, improving transparency and enabling digital interactions between governments and the communities they serve.

Tyler’s product portfolio spans enterprise resource planning and financial management, tax and billing systems, court case and records management, public safety solutions (including computer-aided dispatch and records management), land and property management, permitting and licensing, and enterprise asset management.

See Also Five stocks we like better than Tyler Technologies Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Tyler Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyler Technologies and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINED.A. Davidson & CO. Purchases 24,868 Shares of Toast, Inc. $TOST

NEXT HEADLINE »Acumen Wealth Advisors LLC Raises Stock Holdings in Walmart Inc. $WMT

Posted by Defense World Staff on Jul 22nd, 2026

Bank of New York Mellon Corp lowered its stake in California Resources Corporation (NYSE:CRC – Free Report) by 1.2% during the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,200,610 shares of the oil and gas producer’s stock after selling 14,082 shares during the quarter. Bank of New York Mellon Corp owned approximately 1.35% of California Resources worth $83,106,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its position in shares of California Resources by 363.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 561 shares of the oil and gas producer’s stock valued at $25,000 after acquiring an additional 440 shares in the last quarter. Steward Partners Investment Advisory LLC purchased a new stake in California Resources during the 4th quarter worth about $26,000. Pinnacle Holdings LLC purchased a new stake in California Resources during the 4th quarter worth about $27,000. Valued Wealth Advisors LLC purchased a new stake in California Resources during the 1st quarter worth about $29,000. Finally, Allworth Financial LP raised its stake in California Resources by 328.6% in the 3rd quarter. Allworth Financial LP now owns 780 shares of the oil and gas producer’s stock valued at $41,000 after purchasing an additional 598 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Analysts Set New Price Targets A number of research firms have issued reports on CRC. UBS Group restated a “buy” rating and issued a $70.00 target price (down from $78.00) on shares of California Resources in a report on Monday, July 13th. Mizuho lifted their price target on shares of California Resources from $86.00 to $87.00 and gave the stock an “outperform” rating in a report on Wednesday, May 27th. Stephens set a $85.00 price objective on shares of California Resources and gave the company an “overweight” rating in a research report on Friday. Citigroup reduced their price objective on shares of California Resources from $78.00 to $70.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Finally, Wall Street Zen lowered shares of California Resources from a “buy” rating to a “hold” rating in a research report on Tuesday, June 23rd. One analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, California Resources presently has an average rating of “Moderate Buy” and a consensus price target of $73.09.

Read Our Latest Stock Analysis on California Resources

California Resources Stock Up 2.0% Shares of NYSE:CRC opened at $53.28 on Wednesday. The stock’s 50-day moving average price is $56.55 and its two-hundred day moving average price is $58.10. The company has a current ratio of 0.55, a quick ratio of 0.47 and a debt-to-equity ratio of 0.45. California Resources Corporation has a 12-month low of $43.24 and a 12-month high of $71.98. The firm has a market cap of $4.73 billion, a price-to-earnings ratio of -10.25 and a beta of 0.92.

California Resources (NYSE:CRC – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The oil and gas producer reported $0.88 EPS for the quarter, meeting analysts’ consensus estimates of $0.88. California Resources had a negative net margin of 16.10% and a positive return on equity of 10.12%. The company had revenue of $119.00 million during the quarter, compared to the consensus estimate of $947.50 million. During the same quarter in the prior year, the company posted $1.07 EPS. The company’s quarterly revenue was down 87.0% compared to the same quarter last year. On average, research analysts forecast that California Resources Corporation will post 4.02 EPS for the current year.

California Resources Dividend Announcement The business also recently declared a quarterly dividend, which was paid on Thursday, June 18th. Shareholders of record on Friday, May 29th were paid a dividend of $0.405 per share. The ex-dividend date of this dividend was Friday, May 29th. This represents a $1.62 dividend on an annualized basis and a yield of 3.0%. California Resources’s dividend payout ratio (DPR) is currently -31.15%.

Insider Buying and Selling at California Resources In other news, EVP Jay A. Bys sold 11,907 shares of the business’s stock in a transaction on Monday, July 13th. The shares were sold at an average price of $54.00, for a total transaction of $642,978.00. Following the completion of the sale, the executive vice president directly owned 159,424 shares of the company’s stock, valued at $8,608,896. The trade was a 6.95% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.53% of the stock is currently owned by company insiders.

About California Resources (Free Report)

California Resources Corporation (NYSE: CRC) is an independent exploration and production company focused exclusively on developing oil and natural gas assets in California. Headquartered in Newport Beach, the company engages in hydraulic fracturing, well completions, reservoir management and enhanced recovery operations to produce crude oil, natural gas and natural gas liquids.

CRC’s operations are concentrated in three core regions: the Los Angeles Basin, the Ventura Basin and the San Joaquin Basin.

Recommended Stories Five stocks we like better than California Resources Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding CRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for California Resources Corporation (NYSE:CRC – Free Report).

Receive News & Ratings for California Resources Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for California Resources and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArvest Bank Trust Division Has $956,000 Position in O’Reilly Automotive, Inc. $ORLY

NEXT HEADLINE »Bank of New York Mellon Corp Cuts Stake in Sun Communities, Inc. $SUI

JHVEPhoto/iStock Editorial via Getty Images

Download this episode on Apple Podcasts/Spotify or listen below:

Super Micro (SMCI) rockets higher. (00:14) The clock is ticking for generic drug imports. (01:14) Nike's (NKE) China strategy shift. (02:06)

This is an abridged transcript.

Super Micro Computer (SMCI) shares are up 16% in premarket action after providing fourth quarter preliminary guidance and raising its gross margin outlook.

SMCI also rose 7% on Tuesday.

Super Micro Computer said revenues for the fourth quarter of fiscal year 2026 are estimated to be near the low end of guidance of $11 billion to $12.5 billion. Consensus for fourth quarter revenue is $11.73 billion.

The company said GAAP and non-GAAP gross margins are estimated to be in the range of 15% to 17%, higher than its guidance of 8.2% to 8.4%, primarily due to a favorable customer and product mix.

Backlog rose to record levels at the end of fiscal 2026 with total new orders in excess of $60 billion received during the fourth quarter of fiscal 2026.

These new orders are expected to be delivered over future quarters.

President Trump on Tuesday said generic drugs imported into the U.S. will face zero tariffs for two years starting August 1. After that a 100% levy takes effect in August 2028 and rises to 200% a year later.

The phased schedule is intended to push generic drugmakers to move production onshore.

Trump said in a social media post Tuesday, describing the escalation as “a penalty” for companies that don’t build plants and facilities in the U.S. within the grace period.

Tariffs on patented and branded drugs will remain the same.

In a series of agreements with the Trump administration, over a dozen major pharmaceutical firms, such as Eli Lilly (LLY), Pfizer (PFE), and Novo Nordisk (NVO), have committed to cutting prices across their existing and pipeline drug portfolios.

Nike (NKE) announced that it will cut ties with thousands of online distributors in China starting in January.

Starting next year, Nike’s (NKE) online footprint will shift primarily to the retailer’s official website and app and the storefronts it operates on Tmall, JD.com (JD), and Douyin, some of China’s largest online marketplaces and social platforms.

The change is expected to hurt Nike’s brick-and-mortar partners in the region, which have expanded their online presence recently to grow their businesses.

What’s Trending on Seeking Alpha

SpaceX faces massive share unlocks as investors brace for insider selling

OpenAI models inadvertently hack Hugging Face system during cyber capability evaluation

What will Tesla say during their next earnings call? – Kalshi

Catalyst watch:

Shareholders with Avanos Medical (AVNS) will vote on the buyout offer from American Industrial Partners for $1.27B. Shareholders with Organon (OGN) and Sun Pharmaceutical Industries will both vote on the proposed merger.

AMD (AMD) will hold the AMD Advancing AI event in San Francisco. CEO Dr. Lisa Su will be one of the featured speakers.

Constellation Brands (STZ) will hold its annual meeting. The most sensitive item on the agenda may be the vote on the Long-Term Stock Incentive Plan.

Circana will release its latest report on U.S. video game sales covering the period from May 31 to July 4.

Samsung (SSNLF) will hold its Galaxy Unpacked in London. The headline products are expected to be the Galaxy Z Fold 8, Galaxy Z Flip 8, new Galaxy Watches, and possibly Samsung’s first smart glasses tease. The company's invitation to the event strongly suggests a design-focused reveal.

Stock index futures are lower before the opening bell.

Crude oil is up 5% at $88.

The FTSE 100 is up 0.8% and the DAX is up 0.5 %.

One stock on the biggest movers list: Pegasystems (PEGA) -15% - Shares tumbled after the enterprise software company missed Q2 earnings and revenue estimates and warned that AI-driven market uncertainty was delaying customer buying decisions.

Economic calendar:

10:00 am Atlanta Fed Business Inflation Expectations

10:30 am EIA Petroleum Status Report

An 11th day of U.S. strikes on Iran has futures trending to the downside, says Alex Coffey, as he outlines headlines signaling that the conflict isn't cooling any time soon. In equities, Super Micro (SMCI) surged after the company pledged that its gross margins will nearly double.

Posted by Defense World Staff on Jul 22nd, 2026

ABN Amro Investment Solutions boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 257.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 68,216 shares of the pharmaceutical company’s stock after buying an additional 49,146 shares during the quarter. ABN Amro Investment Solutions’ holdings in Vertex Pharmaceuticals were worth $30,461,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. grew its position in shares of Vertex Pharmaceuticals by 9.1% during the 4th quarter. Assenagon Asset Management S.A. now owns 832,853 shares of the pharmaceutical company’s stock valued at $377,582,000 after buying an additional 69,150 shares during the last quarter. Allworth Financial LP lifted its holdings in shares of Vertex Pharmaceuticals by 414.1% in the 4th quarter. Allworth Financial LP now owns 14,036 shares of the pharmaceutical company’s stock worth $6,363,000 after purchasing an additional 11,306 shares during the last quarter. Calamos Advisors LLC lifted its holdings in shares of Vertex Pharmaceuticals by 77.1% in the 1st quarter. Calamos Advisors LLC now owns 77,886 shares of the pharmaceutical company’s stock worth $34,779,000 after purchasing an additional 33,917 shares during the last quarter. Sandro Wealth Management LLC acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth $1,436,000. Finally, Fideuram Intesa Sanpaolo Private Banking S.P.A. lifted its stake in Vertex Pharmaceuticals by 11.9% in the first quarter. Fideuram Intesa Sanpaolo Private Banking S.P.A. now owns 34,991 shares of the pharmaceutical company’s stock valued at $15,625,000 after buying an additional 3,710 shares during the last quarter. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets In related news, EVP Joy Liu sold 1,104 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $425.02, for a total value of $469,222.08. Following the completion of the transaction, the executive vice president owned 20,729 shares of the company’s stock, valued at approximately $8,810,239.58. This trade represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Ourania Tatsis sold 1,500 shares of the business’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $524.99, for a total transaction of $787,485.00. Following the sale, the executive vice president directly owned 45,321 shares in the company, valued at approximately $23,793,071.79. This trade represents a 3.20% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 18,874 shares of company stock valued at $8,707,966 over the last 90 days. 0.20% of the stock is owned by corporate insiders.

Vertex Pharmaceuticals Stock Up 0.3% Shares of NASDAQ VRTX opened at $482.00 on Wednesday. The stock’s fifty day simple moving average is $464.12 and its 200 day simple moving average is $459.39. The stock has a market capitalization of $122.33 billion, a price-to-earnings ratio of 28.59, a PEG ratio of 2.09 and a beta of 0.29. Vertex Pharmaceuticals Incorporated has a 52-week low of $362.50 and a 52-week high of $533.67.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 EPS for the quarter, beating the consensus estimate of $4.24 by $0.23. Vertex Pharmaceuticals had a return on equity of 23.86% and a net margin of 35.51%.The business had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. During the same period in the prior year, the business posted $4.06 earnings per share. Vertex Pharmaceuticals’s revenue was up 8.3% compared to the same quarter last year. As a group, analysts anticipate that Vertex Pharmaceuticals Incorporated will post 17.01 earnings per share for the current year.

Wall Street Analysts Forecast Growth Several research firms have recently commented on VRTX. Truist Financial upped their price target on shares of Vertex Pharmaceuticals from $542.00 to $560.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Morgan Stanley lifted their price target on Vertex Pharmaceuticals from $612.00 to $616.00 and gave the company an “overweight” rating in a report on Tuesday, May 5th. Canaccord Genuity Group reduced their price objective on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research report on Tuesday, May 5th. UBS Group lifted their target price on Vertex Pharmaceuticals from $545.00 to $585.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Finally, Barclays boosted their price target on Vertex Pharmaceuticals from $607.00 to $615.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Twenty-two analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $559.61.

Check Out Our Latest Stock Analysis on VRTX

About Vertex Pharmaceuticals (Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.

Further Reading Five stocks we like better than Vertex Pharmaceuticals Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report).

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEArvest Bank Trust Division Buys 27,575 Shares of The Walt Disney Company $DIS

NEXT HEADLINE »Arvest Bank Trust Division Acquires 9,475 Shares of Visa Inc. $V

DUNMORE, Pa., July 22, 2026 (GLOBE NEWSWIRE) -- Fidelity D & D Bancorp, Inc. (NASDAQ: FDBC) and its banking subsidiary, The Fidelity Deposit and Discount Bank, announced its unaudited, consolidated financial results for the three and six-month periods ended June 30, 2026.

RESTON, Va.--(BUSINESS WIRE)--John Marshall Bancorp, Inc. (Nasdaq: JMSB) (the “Company”), parent company of John Marshall Bank (the “Bank”), reported net income of $7.0 million for the quarter ended June 30, 2026 compared to $5.1 million for the quarter ended June 30, 2025, an increase of $1.9 million or 37.5%. Diluted earnings per common share were $0.50 for the quarter ended June 30, 2026 compared to $0.36 for the quarter ended June 30, 2025, an increase of 38.9%. Annualized return on average.

HomeEarnings Analysis

SummaryCooling inflation and resilient consumer spending have eased economic concerns, shifting Wall Street's focus squarely to earnings.Big Tech results, beginning on July 22 after the bell, offer fresh insight into AI spending trends and corporate profitability.Rising oil prices and Middle East tensions remain key risks that could challenge the disinflation narrative. Urupong/iStock via Getty Images

It's difficult to call any stretch a calm, quiet summer week, but this one would seemingly fit the bill. Earnings from Alphabet (GOOGL), Tesla (TSLA), and IBM (IBM) are the

379 Followers

Posted by Defense World Staff on Jul 22nd, 2026

Baader Bank Aktiengesellschaft decreased its holdings in Boston Scientific Corporation (NYSE:BSX – Free Report) by 50.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,770 shares of the medical equipment provider’s stock after selling 12,014 shares during the period. Baader Bank Aktiengesellschaft’s holdings in Boston Scientific were worth $728,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also modified their holdings of the stock. Vanguard Group Inc. boosted its holdings in Boston Scientific by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 139,685,997 shares of the medical equipment provider’s stock valued at $13,319,060,000 after purchasing an additional 1,436,550 shares during the period. State Street Corp raised its position in Boston Scientific by 1.4% in the 4th quarter. State Street Corp now owns 65,846,059 shares of the medical equipment provider’s stock valued at $6,278,422,000 after purchasing an additional 920,495 shares in the last quarter. Capital World Investors raised its position in Boston Scientific by 1.9% in the 4th quarter. Capital World Investors now owns 27,151,575 shares of the medical equipment provider’s stock valued at $2,588,953,000 after purchasing an additional 502,627 shares in the last quarter. Norges Bank purchased a new position in shares of Boston Scientific in the 4th quarter valued at about $2,199,395,000. Finally, Morgan Stanley grew its position in shares of Boston Scientific by 10.8% during the fourth quarter. Morgan Stanley now owns 22,960,556 shares of the medical equipment provider’s stock worth $2,189,289,000 after buying an additional 2,246,308 shares in the last quarter. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Boston Scientific Stock Down 1.4% BSX stock opened at $43.14 on Wednesday. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a twelve month low of $42.20 and a twelve month high of $109.50. The company’s 50 day moving average is $47.77 and its two-hundred day moving average is $64.93. The stock has a market cap of $64.12 billion, a P/E ratio of 18.05, a PEG ratio of 0.84 and a beta of 0.58.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion during the quarter, compared to analysts’ expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 EPS. Research analysts expect that Boston Scientific Corporation will post 3.35 earnings per share for the current fiscal year.

Boston Scientific declared that its board has approved a stock repurchase program on Monday, May 18th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s leadership believes its stock is undervalued.

Insider Activity at Boston Scientific In related news, Director Edward J. Ludwig purchased 3,580 shares of Boston Scientific stock in a transaction that occurred on Wednesday, May 20th. The stock was purchased at an average cost of $56.68 per share, with a total value of $202,914.40. Following the completion of the transaction, the director directly owned 25,359 shares in the company, valued at approximately $1,437,348.12. The trade was a 16.44% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Cheryl Pegus acquired 1,770 shares of the company’s stock in a transaction on Wednesday, May 20th. The shares were purchased at an average cost of $56.49 per share, for a total transaction of $99,987.30. Following the acquisition, the director owned 1,770 shares of the company’s stock, valued at approximately $99,987.30. The trade was a ∞ increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders purchased a total of 9,800 shares of company stock valued at $554,012 over the last ninety days. Insiders own 0.34% of the company’s stock.

Analyst Ratings Changes Several analysts recently weighed in on BSX shares. Robert W. Baird set a $70.00 target price on shares of Boston Scientific in a report on Thursday, May 28th. Raymond James Financial reiterated an “outperform” rating and set a $88.00 price target (down from $97.00) on shares of Boston Scientific in a report on Monday, March 30th. Jefferies Financial Group dropped their price objective on shares of Boston Scientific from $100.00 to $67.00 and set a “buy” rating on the stock in a research report on Wednesday, June 24th. Bank of America reduced their price objective on shares of Boston Scientific from $105.00 to $68.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Finally, The Goldman Sachs Group set a $71.00 price objective on shares of Boston Scientific in a research report on Thursday, May 28th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating, four have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $79.84.

Read Our Latest Research Report on Boston Scientific

About Boston Scientific (Free Report)

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.

Featured Articles Five stocks we like better than Boston Scientific Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEBeacon Financial Group Trims Stock Position in Amazon.com, Inc. $AMZN

NEXT HEADLINE »Aware Super Pty Ltd as trustee of Aware Super Makes New $160.61 Million Investment in Meta Platforms, Inc. $META

LGI Homes announces the grand opening of Cypress Gardens in Marana, Arizona, with a Grand Opening Weekend Event on July 25 featuring limited-time incentive

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System lifted its holdings in Kimco Realty Corporation (NYSE:KIM – Free Report) by 3.9% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 1,324,711 shares of the real estate investment trust’s stock after purchasing an additional 50,289 shares during the quarter. California Public Employees Retirement System owned about 0.20% of Kimco Realty worth $29,766,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. State Street Corp raised its holdings in Kimco Realty by 2.2% during the 3rd quarter. State Street Corp now owns 47,382,410 shares of the real estate investment trust’s stock worth $1,035,306,000 after buying an additional 1,034,573 shares during the period. Geode Capital Management LLC lifted its stake in Kimco Realty by 1.2% in the fourth quarter. Geode Capital Management LLC now owns 19,141,842 shares of the real estate investment trust’s stock valued at $386,617,000 after buying an additional 223,936 shares in the last quarter. Invesco Ltd. lifted its stake in Kimco Realty by 34.9% in the fourth quarter. Invesco Ltd. now owns 17,016,898 shares of the real estate investment trust’s stock valued at $344,933,000 after buying an additional 4,399,959 shares in the last quarter. Centersquare Investment Management LLC boosted its holdings in shares of Kimco Realty by 8.1% in the fourth quarter. Centersquare Investment Management LLC now owns 12,905,449 shares of the real estate investment trust’s stock valued at $261,593,000 after buying an additional 970,276 shares during the period. Finally, Daiwa Securities Group Inc. boosted its holdings in shares of Kimco Realty by 0.5% in the third quarter. Daiwa Securities Group Inc. now owns 12,195,113 shares of the real estate investment trust’s stock valued at $266,463,000 after buying an additional 63,054 shares during the period. 89.25% of the stock is owned by institutional investors.

Kimco Realty Trading Up 0.2% NYSE KIM opened at $26.07 on Wednesday. Kimco Realty Corporation has a 52 week low of $19.76 and a 52 week high of $26.45. The company has a debt-to-equity ratio of 0.78, a quick ratio of 3.78 and a current ratio of 3.78. The stock’s 50 day moving average price is $24.75 and its two-hundred day moving average price is $23.25. The stock has a market capitalization of $17.58 billion, a price-to-earnings ratio of 30.32, a PEG ratio of 2.87 and a beta of 0.95.

Kimco Realty (NYSE:KIM – Get Free Report) last issued its quarterly earnings results on Thursday, April 30th. The real estate investment trust reported $0.46 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.01. Kimco Realty had a net margin of 28.54% and a return on equity of 5.82%. The company had revenue of $558.02 million during the quarter, compared to analysts’ expectations of $542.73 million. During the same period last year, the business earned $0.44 EPS. The business’s quarterly revenue was up 4.0% on a year-over-year basis. Kimco Realty has set its FY 2026 guidance at 1.810-1.840 EPS. As a group, analysts anticipate that Kimco Realty Corporation will post 1.83 earnings per share for the current fiscal year.

Kimco Realty Dividend Announcement The firm also recently announced a quarterly dividend, which was paid on Thursday, June 18th. Investors of record on Friday, June 5th were issued a dividend of $0.26 per share. The ex-dividend date was Friday, June 5th. This represents a $1.04 annualized dividend and a yield of 4.0%. Kimco Realty’s dividend payout ratio is presently 120.93%.

Analyst Upgrades and Downgrades Several brokerages have recently issued reports on KIM. Truist Financial increased their price objective on shares of Kimco Realty from $23.00 to $25.00 and gave the stock a “hold” rating in a research report on Thursday, May 28th. Stifel Nicolaus set a $28.00 price objective on shares of Kimco Realty in a research report on Thursday, June 11th. Scotiabank upped their target price on shares of Kimco Realty from $24.00 to $25.00 and gave the stock a “sector perform” rating in a research note on Tuesday, May 19th. Evercore set a $25.00 target price on shares of Kimco Realty in a research note on Friday, May 1st. Finally, UBS Group increased their target price on Kimco Realty from $26.00 to $29.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat.com, Kimco Realty currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.06.

View Our Latest Stock Report on Kimco Realty

Kimco Realty Profile (Free Report)

Founded in 1958 by Milton Cooper and headquartered in Jericho, New York, Kimco Realty Corporation (NYSE: KIM) is a leading publicly traded real estate investment trust (REIT) specializing in the ownership, operation and development of open-air shopping centers. The company’s portfolio, concentrated on neighborhood and community centers anchored by grocery stores, encompasses approximately 400 properties across the United States, with selective holdings in Canada and Mexico.

Kimco’s core business activities include acquiring, repositioning and managing retail real estate assets that serve as daily-need destinations for consumers.

Read More Five stocks we like better than Kimco Realty Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Kimco Realty Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kimco Realty and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Decreases Stake in HP Inc. $HPQ

NEXT HEADLINE »Alliant Energy Corporation $LNT Shares Sold by California Public Employees Retirement System

Posted by Defense World Staff on Jul 22nd, 2026

Bessemer Group Inc. lowered its stake in Bio-Techne Corp (NASDAQ:TECH – Free Report) by 13.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 61,962 shares of the biotechnology company’s stock after selling 9,722 shares during the quarter. Bessemer Group Inc.’s holdings in Bio-Techne were worth $3,238,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of TECH. Goldman Sachs Group Inc. lifted its position in shares of Bio-Techne by 12.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,063,939 shares of the biotechnology company’s stock valued at $62,379,000 after acquiring an additional 113,634 shares in the last quarter. Woodline Partners LP grew its position in Bio-Techne by 40.0% during the 1st quarter. Woodline Partners LP now owns 13,356 shares of the biotechnology company’s stock worth $783,000 after purchasing an additional 3,814 shares in the last quarter. EverSource Wealth Advisors LLC grew its position in Bio-Techne by 506.3% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 562 shares in the last quarter. First Trust Advisors LP raised its stake in Bio-Techne by 1,085.7% during the 2nd quarter. First Trust Advisors LP now owns 105,418 shares of the biotechnology company’s stock valued at $5,424,000 after purchasing an additional 96,527 shares during the period. Finally, Natixis lifted its holdings in shares of Bio-Techne by 82.6% in the second quarter. Natixis now owns 24,991 shares of the biotechnology company’s stock valued at $1,286,000 after purchasing an additional 11,306 shares in the last quarter. 98.95% of the stock is owned by hedge funds and other institutional investors.

Bio-Techne Price Performance NASDAQ TECH opened at $71.63 on Wednesday. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $11.22 billion, a PE ratio of 103.81, a price-to-earnings-growth ratio of 8.53 and a beta of 1.29. Bio-Techne Corp has a 12-month low of $43.19 and a 12-month high of $72.16. The company has a 50 day moving average price of $58.84 and a two-hundred day moving average price of $58.56.

Bio-Techne (NASDAQ:TECH – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a net margin of 9.05% and a return on equity of 13.57%. The business had revenue of $311.42 million for the quarter, compared to the consensus estimate of $316.11 million. During the same quarter in the prior year, the business posted $0.56 EPS. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. As a group, equities analysts predict that Bio-Techne Corp will post 1.65 earnings per share for the current fiscal year.

Bio-Techne Announces Dividend The business also recently disclosed a quarterly dividend, which was paid on Friday, May 29th. Investors of record on Monday, May 18th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.4%. The ex-dividend date of this dividend was Monday, May 18th. Bio-Techne’s dividend payout ratio (DPR) is presently 46.38%.

Wall Street Analyst Weigh In A number of research analysts have recently weighed in on TECH shares. William Blair downgraded Bio-Techne from an “outperform” rating to a “market perform” rating in a report on Thursday, June 25th. Citigroup cut Bio-Techne from a “buy” rating to a “neutral” rating and lifted their target price for the company from $70.00 to $73.00 in a research note on Friday, June 26th. Leerink Partners set a $73.00 price objective on shares of Bio-Techne in a research report on Thursday, June 25th. Piper Sandler assumed coverage on shares of Bio-Techne in a research report on Thursday, June 11th. They issued a “neutral” rating and a $65.00 target price for the company. Finally, Stephens set a $73.00 price target on shares of Bio-Techne and gave the company an “equal weight” rating in a report on Friday, June 26th. Three investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $68.08.

Read Our Latest Stock Report on Bio-Techne

About Bio-Techne (Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.

Further Reading Five stocks we like better than Bio-Techne Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Techne Corp (NASDAQ:TECH – Free Report).

Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Buys 904 Shares of First Citizens BancShares, Inc. $FCNCA

NEXT HEADLINE »Andra AP fonden Increases Stake in The Travelers Companies, Inc. $TRV

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, July 22, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor.

Fifth Third Bancorp boosted its holdings in InterDigital, Inc. (NASDAQ: IDCC) by 1,017.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 7,105 shares of the Wireless communications provider's stock after acquiring an additional 6,469 shares during the period. Fifth Third

Posted by Defense World Staff on Jul 22nd, 2026

California Public Employees Retirement System decreased its holdings in shares of Alliant Energy Corporation (NASDAQ:LNT – Free Report) by 32.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 436,395 shares of the company’s stock after selling 207,817 shares during the quarter. California Public Employees Retirement System owned about 0.17% of Alliant Energy worth $31,316,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Glenmede Investment Management LP lifted its stake in shares of Alliant Energy by 0.7% during the third quarter. Glenmede Investment Management LP now owns 22,793 shares of the company’s stock worth $1,536,000 after purchasing an additional 153 shares in the last quarter. Quadrant Capital Group LLC grew its stake in shares of Alliant Energy by 1.8% in the third quarter. Quadrant Capital Group LLC now owns 9,117 shares of the company’s stock valued at $615,000 after buying an additional 158 shares in the last quarter. Apollon Wealth Management LLC grew its stake in shares of Alliant Energy by 4.8% in the fourth quarter. Apollon Wealth Management LLC now owns 3,517 shares of the company’s stock valued at $229,000 after buying an additional 161 shares in the last quarter. Simplicity Wealth LLC raised its holdings in shares of Alliant Energy by 5.5% during the 4th quarter. Simplicity Wealth LLC now owns 3,216 shares of the company’s stock valued at $209,000 after buying an additional 167 shares during the period. Finally, Resonant Capital Advisors LLC lifted its position in Alliant Energy by 4.6% during the 1st quarter. Resonant Capital Advisors LLC now owns 4,182 shares of the company’s stock worth $300,000 after acquiring an additional 184 shares in the last quarter. 79.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth LNT has been the subject of a number of analyst reports. Scotiabank restated a “sector perform” rating and issued a $74.00 price target (up from $72.00) on shares of Alliant Energy in a report on Monday, May 4th. BMO Capital Markets reissued an “outperform” rating and set a $83.00 target price (up from $81.00) on shares of Alliant Energy in a research report on Wednesday, July 15th. Mizuho set a $76.00 target price on shares of Alliant Energy in a research note on Monday, May 4th. Wells Fargo & Company reaffirmed an “overweight” rating and set a $76.00 price target on shares of Alliant Energy in a report on Tuesday, April 21st. Finally, Weiss Ratings raised shares of Alliant Energy from a “buy (b)” rating to a “buy (b+)” rating in a research note on Tuesday, July 7th. Nine equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat.com, Alliant Energy has a consensus rating of “Moderate Buy” and an average price target of $77.36.

View Our Latest Stock Analysis on Alliant Energy

Alliant Energy Price Performance Shares of NASDAQ LNT opened at $73.11 on Wednesday. The company has a quick ratio of 0.53, a current ratio of 0.69 and a debt-to-equity ratio of 1.48. Alliant Energy Corporation has a fifty-two week low of $63.28 and a fifty-two week high of $78.81. The business has a 50 day moving average price of $74.00 and a two-hundred day moving average price of $71.42. The firm has a market cap of $18.88 billion, a PE ratio of 22.92, a price-to-earnings-growth ratio of 3.02 and a beta of 0.55.

Alliant Energy (NASDAQ:LNT – Get Free Report) last announced its earnings results on Thursday, April 30th. The company reported $0.82 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.82. The company had revenue of $1.18 billion for the quarter, compared to analyst estimates of $1.08 billion. Alliant Energy had a return on equity of 11.37% and a net margin of 18.58%.Alliant Energy’s quarterly revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.83 EPS. Alliant Energy has set its FY 2026 guidance at 3.360-3.460 EPS. Sell-side analysts expect that Alliant Energy Corporation will post 3.43 earnings per share for the current fiscal year.

Alliant Energy Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Friday, July 31st will be paid a dividend of $0.535 per share. This represents a $2.14 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, July 31st. Alliant Energy’s dividend payout ratio is 67.08%.

Alliant Energy Company Profile (Free Report)

Alliant Energy Corporation (NASDAQ: LNT) is a publicly traded energy holding company headquartered in Madison, Wisconsin, that provides regulated electric and natural gas utility services in the American Midwest. The company serves customers primarily in Wisconsin and Iowa through its regulated utility subsidiaries and operates as an integrated provider responsible for generation, transmission and distribution of energy to residential, commercial and industrial customers.

Alliant Energy’s core activities include operating and maintaining electric generation assets, managing the regional transmission and distribution network, and delivering natural gas service to its franchise territories.

Featured Articles Five stocks we like better than Alliant Energy Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for Alliant Energy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliant Energy and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINECalifornia Public Employees Retirement System Acquires 50,289 Shares of Kimco Realty Corporation $KIM

NEXT HEADLINE »California Public Employees Retirement System Has $29.32 Million Stock Holdings in Coeur Mining, Inc. $CDE

California Public Employees Retirement System lessened its holdings in shares of Rollins, Inc. (NYSE: ROL) by 11.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 645,835 shares of the business services provider's stock after selling 87,257 shares during the period. California Public Employees

Sameer to drive growth, investment in wealth management business

, /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced Shimna Sameer as head of Truist Wealth. Sameer joins the company to accelerate the performance and scale the delivery of Truist's wealth management business.

As head of Truist Wealth, Sameer will have broad oversight of business strategy, including the delivery of Truist's purpose-driven wealth experience to clients, enhancing the advisor and client experience, investing in and deploying innovative technology, strengthening partnerships across the enterprise and delivering long-term growth.

Shimna Sameer announced head of Truist Wealth. Sameer has more than 20 years of experience in consumer banking, wealth management and private banking. Most recently, she served as head of products, solutions and platforms at Bank of America Private Bank. In this role, Sameer was responsible for managing the Private Bank's digital platforms, business and talent strategies and client experience, as well as driving business opportunities across the enterprise. She also led the delivery of the firm's specialized capabilities – including wealth strategy, trust services, custom lending and art services – to all of Bank of America's wealth management clients. Throughout her career, Sameer has led scaled client-facing businesses and large transformational initiatives, including developing the strategy for the sales organization, digital solutions and talent development for Merrill Edge.

Sameer will join Truist in October, reporting to Chief Wholesale Banking Officer Kristin Lesher, and serve as a member of the Truist Operating Council. She will be based in Truist's Hudson Yards offices in New York City.

"Truist Wealth is critical to our enterprise growth strategy and we'll continue to invest in technology enhancements, empower our advisors and broaden the solutions we provide clients," said Kristin Lesher, Truist Chief Wholesale Banking Officer. "Shim has spent her career serving clients, leading organizations to achieve outsized results and designing and implementing strategies that drive performance. She has a proven ability to partner across the enterprise, support advisor growth and development and leverage technology to scale businesses. Her experience and success across banking and wealth management will shape Truist Wealth at an important moment in our business."

Truist Wealth delivers holistic wealth management solutions to affluent, high, and ultra-high net worth individuals, families, and business owners across the U.S. and abroad. Truist Wealth is part of the Truist Wholesale Banking segment which provides comprehensive solutions to commercial, corporate, institutional and high-net-worth clients through a combination of regional coverage and industry-focused teams serving clients across the U.S.

About Truist

Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $556 billion as of June 30, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

About Truist Wealth

Truist Wealth delivers holistic wealth management solutions to affluent, high, and ultra-high net worth individuals, families, and business owners across the U.S. and abroad. Truist Wealth provides distinct solutions for individuals and businesses through the following affiliates: Banking products and services, corporate trust, escrow, and institutional investment management services to public, private, and nonprofit organizations provided by Truist Bank, Member FDIC. Securities, brokerage accounts, and/or annuities offered by Truist Investment Services, Inc., member FINRA, SIPC, and a licensed insurance agency. Investment advisory services offered by Truist Advisory Services, Inc. and affiliated SEC registered investment advisers.

SOURCE Truist Financial Corporation

Americké futures kontrakty ztrácejí

July 22, 2026 08:00 ET  | Source: LB Pharmaceuticals Inc

NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases, today announced that based on enrollment projections, it now expects to report topline results from the pivotal Phase 3 NOVA-2 clinical trial of LB-102 in patients with schizophrenia in the first half of 2027 and to schedule a pre-NDA meeting with the FDA thereafter in the second half of 2027. NOVA-2 is a pivotal Phase 3 multi-center, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of LB-102 for the treatment of schizophrenia. The trial is designed to enroll approximately 460 patients across 25 sites in the U.S. 

“Enrollment in our pivotal Phase 3 NOVA-2 trial has been more rapid than we expected, which we believe is a reflection of both the strength of our execution and the level of interest in LB-102 as a potential new treatment for schizophrenia. Based on the pace of enrollment since initiating NOVA-2, we now expect to report topline results in the first half of 2027, ahead of our prior guidance of the second half of 2027, and to schedule a pre-NDA meeting soon thereafter in the second half of 2027,” said Heather Turner, Chief Executive Officer of LB Pharmaceuticals. “We remain well capitalized with a cash runway expected to fund operations into the second quarter of 2029 through multiple clinical readouts, with topline data from the Phase 2 ILLUMINATE-1 trial of LB-102 in bipolar depression expected in the first quarter of 2028, and from the Phase 2 trial of LB-102 in adjunctive MDD in the first half of 2029.”

About LB-102

LB-102 is a novel, once-daily, orally administered investigational small molecule and potential first benzamide antipsychotic in the United States for the treatment of neuropsychiatric disorders. A methylated derivative of amisulpride, a widely used antipsychotic outside the United States, LB-102 was developed to retain amisulpride’s benefits while addressing its limitations. LB-102 is a potent and selective antagonist of D2, D3, and 5HT-7 receptors with few off-target effects and broad therapeutic potential across psychosis and mood disorders. In early 2025, LB Pharmaceuticals announced positive data from a four-week placebo-controlled, double-blinded, Phase 2 trial in patients with acute schizophrenia. In this trial, LB-102 demonstrated statistically significant benefit versus placebo at all doses studied, including rapid onset of effect at week 1 and sustained benefit through the endpoint of the trial, a potentially class-leading safety profile with low rates of EPS (including akathisia), minimal sedation and few GI side effects, alongside effects on negative symptoms and cognitive performance. These data underscore LB-102’s potential to address multiple dimensions of neuropsychiatric illness. The pivotal Phase 3 NOVA-2 trial of LB-102 for acute schizophrenia and the Phase 2 ILLUMINATE-1 trial of LB-102 for bipolar 1 depression are ongoing, and a Phase 2 trial of LB-102 in adjunctive treatment of MDD is planned. Additional expansion opportunities for LB-102 include predominantly negative symptoms of schizophrenia, Alzheimer’s disease psychosis and agitation, as well as other neuropsychiatric diseases. 

About LB Pharmaceuticals

LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.

Cautionary Note Regarding Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” or similar expressions are intended to identify forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the expected clinical development and regulatory pathway and therapeutic benefits of LB-102; the design, objectives, initiation, timing, progress and results of clinical trials of LB-102, including the pivotal Phase 3 NOVA-2 trial in acute schizophrenia, our open label trial (NOVA-3), the Phase 2 ILLUMINATE-1 trial in bipolar 1 depression and the Phase 2 trial for the adjunctive treatment of MDD; and anticipated cash runway into the second quarter of 2029. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These risks and uncertainties include, among others: the Company’s limited operating history and historical losses; the Company’s ability to raise additional funding to complete the development and any commercialization of LB-102; the Company’s dependence on the success of its lead product candidate, LB-102; the Company’s ability to obtain regulatory approval of and successfully commercialize its product candidate; the early stages of clinical development of the Company’s lead product candidate, LB-102; any undesirable side effects or other properties of the Company’s product candidate; that the Company may be delayed in initiating, enrolling or completing any clinical trials; competition from third parties that are developing products for similar uses; the Company’s ability to obtain, maintain and protect its intellectual property; and the Company’s dependence on third parties in connection with manufacturing, clinical trials and preclinical studies.

These and other risks are described more fully in the section titled “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2026 and its other documents to be subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media and Investor Contact: 
Ellen Rose
[email protected]

Posted by Defense World Staff on Jul 22nd, 2026

Arvest Bank Trust Division lessened its position in O’Reilly Automotive, Inc. (NASDAQ:ORLY – Free Report) by 42.9% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 10,357 shares of the specialty retailer’s stock after selling 7,786 shares during the period. Arvest Bank Trust Division’s holdings in O’Reilly Automotive were worth $956,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. Vanguard Group Inc. lifted its stake in O’Reilly Automotive by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 79,730,143 shares of the specialty retailer’s stock valued at $7,272,186,000 after buying an additional 458,613 shares in the last quarter. State Street Corp increased its position in shares of O’Reilly Automotive by 0.4% in the fourth quarter. State Street Corp now owns 37,206,098 shares of the specialty retailer’s stock valued at $3,393,568,000 after acquiring an additional 140,387 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of O’Reilly Automotive by 1.6% during the 4th quarter. Geode Capital Management LLC now owns 24,140,497 shares of the specialty retailer’s stock worth $2,201,555,000 after purchasing an additional 372,896 shares in the last quarter. Wellington Management Group LLP lifted its stake in O’Reilly Automotive by 25.1% in the fourth quarter. Wellington Management Group LLP now owns 14,755,276 shares of the specialty retailer’s stock valued at $1,345,829,000 after acquiring an additional 2,964,945 shares during the last quarter. Finally, Norges Bank acquired a new stake in O’Reilly Automotive in the 4th quarter valued at about $1,134,311,000. Institutional investors and hedge funds own 85.00% of the company’s stock.

Analyst Upgrades and Downgrades A number of equities analysts have commented on the stock. Citigroup reaffirmed a “buy” rating and set a $115.00 price objective (up from $110.00) on shares of O’Reilly Automotive in a research report on Friday, May 1st. Raymond James Financial reaffirmed an “outperform” rating and issued a $115.00 price objective on shares of O’Reilly Automotive in a report on Friday, May 1st. Wolfe Research set a $98.00 price target on shares of O’Reilly Automotive in a report on Wednesday, July 15th. Mizuho raised their price objective on O’Reilly Automotive from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Finally, Robert W. Baird set a $110.00 target price on shares of O’Reilly Automotive in a research note on Friday, May 1st. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, O’Reilly Automotive has an average rating of “Moderate Buy” and an average target price of $110.70.

Get Our Latest Research Report on ORLY

O’Reilly Automotive Price Performance Shares of O’Reilly Automotive stock opened at $87.97 on Wednesday. The firm has a market cap of $72.90 billion, a price-to-earnings ratio of 28.75, a PEG ratio of 1.86 and a beta of 0.51. O’Reilly Automotive, Inc. has a one year low of $82.59 and a one year high of $108.71. The stock’s 50-day moving average is $88.55 and its 200 day moving average is $91.83.

O’Reilly Automotive (NASDAQ:ORLY – Get Free Report) last released its quarterly earnings data on Wednesday, April 29th. The specialty retailer reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.03. The company had revenue of $4.56 billion during the quarter, compared to analyst estimates of $4.46 billion. O’Reilly Automotive had a net margin of 14.30% and a negative return on equity of 263.22%. O’Reilly Automotive’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted $9.35 EPS. O’Reilly Automotive has set its FY 2026 guidance at 3.150-3.250 EPS. On average, sell-side analysts expect that O’Reilly Automotive, Inc. will post 3.24 EPS for the current fiscal year.

Insider Activity In related news, CEO Brad W. Beckham sold 13,635 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $95.00, for a total value of $1,295,325.00. Following the transaction, the chief executive officer directly owned 12,250 shares in the company, valued at $1,163,750. This trade represents a 52.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, SVP Philip M. Hopper sold 3,700 shares of the company’s stock in a transaction on Thursday, May 7th. The stock was sold at an average price of $94.60, for a total transaction of $350,020.00. Following the transaction, the senior vice president owned 4,888 shares in the company, valued at approximately $462,404.80. The trade was a 43.08% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 105,730 shares of company stock valued at $9,815,388. Corporate insiders own 0.77% of the company’s stock.

About O’Reilly Automotive (Free Report)

O’Reilly Automotive, Inc is a leading retailer and distributor in the automotive aftermarket, supplying parts, tools, supplies and accessories for both professional service providers and do‑it‑yourself (DIY) customers. The company’s product assortment covers replacement parts, maintenance items, performance parts, collision components and shop equipment, complemented by diagnostic tools, batteries, chemicals and consumables. O’Reilly serves customers through company-operated retail stores, commercial sales programs for repair shops and maintenance fleets, and digital channels that support parts lookup, ordering and fulfillment.

The company operates a broad supply chain that includes regional distribution centers to support rapid replenishment of store inventory and commercial deliveries.

Featured Articles Five stocks we like better than O’Reilly Automotive Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible

Receive News & Ratings for O'Reilly Automotive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for O'Reilly Automotive and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEAcumen Wealth Advisors LLC Reduces Stock Holdings in ASML Holding N.V. $ASML

Andra AP fonden grew its holdings in shares of Marvell Technology, Inc. (NASDAQ:MRVL – Free Report) by 1,800.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 162,907 shares of the semiconductor company’s stock after purchasing an additional 154,335 shares during the quarter. Andra AP fonden’s holdings in Marvell Technology were worth $16,136,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of MRVL. State Street Corp lifted its stake in shares of Marvell Technology by 7.9% in the fourth quarter. State Street Corp now owns 22,834,816 shares of the semiconductor company’s stock worth $1,940,503,000 after buying an additional 1,677,724 shares in the last quarter. Geode Capital Management LLC grew its stake in Marvell Technology by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 12,108,452 shares of the semiconductor company’s stock valued at $1,025,185,000 after acquiring an additional 97,624 shares in the last quarter. Norges Bank purchased a new stake in Marvell Technology during the 4th quarter valued at about $895,455,000. Van ECK Associates Corp raised its holdings in Marvell Technology by 11.4% in the 4th quarter. Van ECK Associates Corp now owns 9,864,514 shares of the semiconductor company’s stock valued at $838,286,000 after acquiring an additional 1,007,315 shares during the last quarter. Finally, Northern Trust Corp lifted its stake in Marvell Technology by 9.7% in the 4th quarter. Northern Trust Corp now owns 6,798,272 shares of the semiconductor company’s stock worth $577,717,000 after purchasing an additional 598,920 shares in the last quarter. Hedge funds and other institutional investors own 83.51% of the company’s stock.

Wall Street Analyst Weigh In A number of equities analysts have weighed in on the company. Jefferies Financial Group boosted their price objective on Marvell Technology from $149.00 to $235.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Melius Research set a $220.00 price target on Marvell Technology in a research report on Monday, May 18th. Loop Capital raised Marvell Technology to a “strong-buy” rating in a research report on Tuesday, June 16th. Raymond James Financial set a $235.00 price target on Marvell Technology and gave the stock a “strong-buy” rating in a report on Thursday, May 28th. Finally, Stifel Nicolaus raised their price target on Marvell Technology from $321.00 to $350.00 and gave the stock a “buy” rating in a research note on Wednesday, June 24th. Three equities research analysts have rated the stock with a Strong Buy rating, twenty-seven have issued a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $245.45.

Check Out Our Latest Research Report on Marvell Technology

Insider Activity In related news, CEO Matthew J. Murphy sold 7,500 shares of the business’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $177.26, for a total value of $1,329,450.00. Following the completion of the transaction, the chief executive officer owned 739,397 shares of the company’s stock, valued at approximately $131,065,512.22. The trade was a 1.00% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sandeep Bharathi sold 2,231 shares of the company’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $299.13, for a total transaction of $667,359.03. Following the completion of the transaction, the insider owned 55,530 shares in the company, valued at approximately $16,610,688.90. This trade represents a 3.86% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 45,981 shares of company stock worth $9,835,542 in the last quarter. Corporate insiders own 0.12% of the company’s stock.

Marvell Technology Stock Performance Shares of MRVL stock opened at $207.96 on Wednesday. The stock has a market cap of $181.92 billion, a PE ratio of 71.22, a P/E/G ratio of 1.28 and a beta of 2.20. The company has a debt-to-equity ratio of 0.27, a quick ratio of 2.66 and a current ratio of 3.28. Marvell Technology, Inc. has a 1 year low of $61.44 and a 1 year high of $329.88. The stock has a fifty day moving average price of $241.88 and a 200 day moving average price of $151.14.

Marvell Technology (NASDAQ:MRVL – Get Free Report) last released its quarterly earnings data on Wednesday, May 27th. The semiconductor company reported $0.80 EPS for the quarter, hitting the consensus estimate of $0.80. The business had revenue of $2.42 billion for the quarter, compared to analyst estimates of $2.41 billion. Marvell Technology had a net margin of 28.99% and a return on equity of 13.83%. The business’s revenue for the quarter was up 27.6% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.62 EPS. Marvell Technology has set its Q2 2027 guidance at 0.880-0.980 EPS. Sell-side analysts forecast that Marvell Technology, Inc. will post 3.07 earnings per share for the current fiscal year.

Marvell Technology Dividend Announcement The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 30th. Stockholders of record on Friday, July 10th will be given a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 0.1%. The ex-dividend date is Friday, July 10th. Marvell Technology’s dividend payout ratio is currently 8.22%.

More Marvell Technology News Here are the key news stories impacting Marvell Technology this week:

Positive Sentiment: Marvell is benefiting from renewed enthusiasm for AI infrastructure spending, which lifted semiconductor stocks across the market and helped chip names like MRVL rally. Marvell Stock Jumps As AI Infrastructure Spending Boom Powers Semiconductor Rally Positive Sentiment: Market coverage highlighted Marvell among the chip leaders powering a Nasdaq rebound, with investors buying back into memory and AI-related semiconductor stocks after recent weakness. Stock Market Today: Nasdaq Higher As Memory Chip Names Rally; Schwab Slides (Live Coverage) Positive Sentiment: Analysts and media pieces pointed to Marvell’s strong first-half performance and improving growth profile, reinforcing the view that the stock remains a key AI infrastructure play. Why Marvell Jumped 251% in the First Half of the Year Neutral Sentiment: Several commentary pieces noted that Marvell’s valuation has become a renewed topic of debate, suggesting the rally may face scrutiny if growth expectations cool. Marvell Technology (MRVL) Rises With AI Chip Rally As Valuation Questions Return Negative Sentiment: Some articles reminded investors that Marvell is still well below its recent highs, with caution that the stock’s earlier AI-driven surge may have outpaced fundamentals. Marvell Technology: The Stock Is Down 39% From Its High. Time to Buy the Dip? About Marvell Technology (Free Report)

Marvell Technology Group is a global semiconductor company that designs and develops integrated circuits and related software for data infrastructure, networking, storage and connectivity markets. The company’s product portfolio includes system-on-chip (SoC) solutions, Ethernet physical-layer transceivers (PHYs), switch and switch silicon, optical interconnect components, storage controllers, and security processors. Marvell’s technology is used to enable high-performance data centers, carrier networks, enterprise and cloud storage, as well as connectivity in automotive and industrial applications.

Founded in 1995 and headquartered in Santa Clara, California, Marvell has grown through both organic development and strategic acquisitions to broaden its capabilities across networking and data interconnect.

See Also Five stocks we like better than Marvell Technology Confidence Is Back, But Earnings Show the Consumer Is Being Picky AeroVironment’s Stock Is Down, But Drone Demand Is Taking Off 3M’s Redemption Arc: Can Q2 Earnings Change the Narrative? 3 Photonics Companies Making Quantum Tech Possible Want to see what other hedge funds are holding MRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Marvell Technology, Inc. (NASDAQ:MRVL – Free Report).

Receive News & Ratings for Marvell Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marvell Technology and related companies with MarketBeat.com's FREE daily email newsletter.

Since 2007, Monster Beverage Corporation (MNST) rises1,668% due to outlier inflows.

MNST develops, markets, distributes, and sells 11 different brands of drinks and concentrates, including its namesake Monster Energy brand. MNST’s first-quarter fiscal 2026 report showed quarterly net sales of $2.35 billion (a 26.9% rise), double-digit growth in all regions, net income per diluted share of $0.58 (a 27.6% rise), as well as returning $100 million to shareholders through repurchases. The company reports again on July 30.

It’s no wonder MNST shares are up 23% so far this year – and they could rise more. MoneyFlows data shows how Big Money investors are again betting heavily on the stock

Institutions Thirsty for Monster Beverage Institutional volumes reveal plenty. Over the last year, MNST has enjoyed strong investor demand, which we believe to be institutional support.

Each green bar signals unusually large volumes in MNST shares. They reflect our proprietary inflow signal, pushing the stock higher:

MNST garnered many institutional inflows over the course of a year versus just two outflows, pushing shares up 59%. Source: www.moneyflows.com Plenty of staples names are under accumulation right now. But there’s a powerful fundamental story happening with Monster Beverage.

Monster Beverage Fundamental Analysis Institutional support and a healthy fundamental backdrop make this company worth investigating. As you can see, MNST has had strong sales and earnings growth:

3-year sales growth rate (+9.6%) 3-year earnings growth rate (+21.4%) Source: FactSet

Also, EPS is estimated to ramp higher this year by +13.1%.

Now it makes sense why the stock has been powering to new heights. MNST has a track record of strong financial performance.

Marrying great fundamentals with our proprietary software has found some big winning stocks over the long term.

Monster Beverage has been a top-rated stock at MoneyFlows. That means the stock has unusual buy pressure and growing fundamentals. We have a ranking process that showcases stocks like this on a weekly basis.

It’s made the rare Outlier 20 report 92 times since 2007, gaining 1,668%. The blue bars below show when MNST was a top pick in the last year…institutional support drives prices higher:

A total of 14 outlier inflows from institutional investors in the last year pushed prices higher – MNST has 92 total outlier inflows and no outflows since 2007. Source: www.moneyflows.com Tracking unusual volumes reveals the power of money flows.

This is a trait that most outlier stocks exhibit…the best of the best. Big Money demand drives stocks upward.

Monster Beverage Price Prediction The MNST rally isn’t new at all. Big Money buying in the shares is signaling to take notice. Given the historical gains in share price and strong fundamentals, this stock could be worth a spot in a diversified portfolio.

Disclosure: the author holds no position in MNST at the time of publication.

If you are a Registered Investment Advisor (RIA) or are a serious investor, take your investing to the next level, learn more about the MoneyFlows process here.